Taiwan biopharma company OBI Pharma Inc (TPEx:4174) reported on Thursday the receipt of the US Food and Drug Administration's (FDA) clearance for an investigational new drug (IND) application for a Phase I/II study of OBI-3424 in solid and liquid tumors in cancer patients who over-express AKR1C3.
Following the US FDA's clearance, the company intends to enroll patients with local solid tumors, including hepatocellular carcinoma (HCC) and castrate-resistant prostate cancer (CRPC).
OBI-3424 is a first-in-class novel small-molecule prodrug that selectively targets cancers overexpressing the enzyme aldo-keto reductase 1C3 (AKR1C3) and selectively releases a potent DNA alkylating agent in the presence of the AKR1C3 enzyme. AKR1C3 is highly expressed in up to 15 solid and liquid tumors, added the company.
According to the company's chief medical advisor, Tillman Pearce, M.D., this clinical trial intends to verify the safety and preliminary activity profile of OBI-3424 in a variety of solid and liquid tumors.
The company will conduct this first-in-man clinical trial at the University of Texas M.D. Anderson Cancer Center and The James Cancer Hospital and Solove Research Institute of Ohio State University, two of America's leading academic oncology research institutions, added Dr Pearce.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886